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Aim
To study the spectrum of malignancies in human immun-
odeficiency virus (HIV)-infected children and the clinical
outcome of patients with these tumors.
Methods
An observational study was done of pediatric patients
diagnosed with cancer and who were HIV-infected at the
Tata Memorial Cancer Hospital, a tertiary referral cancer
centre in Mumbai, India. The study period was 2001 to
2007. Data regarding demographic profiles, types of can-
cers, stage of cancer, treatment and outcome, immune sta-
tus was analyzed. We used gender and age-specific
proportions of pediatric cancer which were recorded in
the Tata Hospital cancer registry in 2002 to estimate an
expected number of pediatric cancers among HIV positive
pediatric cancer patients during the 2001 to 2007. The
proportional incidence ratio (PIR) was calculated.
Results
The hospital diagnosed 475 patients including adults and
children with HIV and cancer between 2001 and 2007.
Among them there were 11 children with HIV infection
and cancer. All children except one were male. The
median age was 7 years (range 4 to 12 years). All patients
were HIV-infected by vertical transmission. Malignancy
was the presenting illness in four (36.3%) patients, after
which the parents were diagnosed to be HIV-positive. All
patients were HBsAg and HCV negative. CD4 counts were
done in seven patients and the CD4 percentage was less
than 14 percent in two patients. None of the children
received HAART prior to being diagnosed with cancer.
Four patients were started on concomitant chemotherapy
and HAART. Nine patients (81.8%) had Non-Hodgkin's
lymphoma (NHL); there was one case (9%) of B-ALL
(acute lymphatic leukemia) and one case (9%) of Hodg-
kin's disease. Among the NHL patients the histology
included four cases of diffuse large B-cell lymphoma
(DLBCL), two cases of plasmablastic and two cases of
Burkitt's lymphoma, and one case of high grade lym-
phoma. One-third (33.33%) of the patients had extra
nodal disease and 66.66% of patients had advanced dis-
ease (stage III and IV). The PIR for NHL in male children
was 9.71 (95% CI 4.19–19.13). Out of the 11 patients,
seven (63.6%) received cancer directed treatment. Three
patients received chemotherapy and radiotherapy and
four patients received only chemotherapy.
One patient received prophylactic GCSF throughout
chemotherapy and three received only with some cycles of
CT after development of neutropenia. Adverse events
included febrile neutropenia (71.4%), candidiasis
(42.8%), diarrhea (42.8%), otitis (28.5%), CMV entero-
colitis (28.5%), varicella (14.2%), pulmonary tuberculo-
sis (14.2%), mucositis (71.4%), and hemorrhagic cystitis
(28.5%). Of the seven patients who received treatment,
two (28.5%) showed complete response, three (42.8%)
had progressive disease, one (14.2%) was lost to follow
up and one patient (14.2%) is currently on therapy. Of
the 11 patients, five expired: four patients died to disease
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progression and one patient died of infectious complica-
tion. The overall survival was 22.2 percent at 1 year.
Conclusion
NHL is the most common cancer among HIV-infected
children and the PIR was significantly increased. Cancer
may be the presenting AIDS-defining illness in HIV-
infected children. Malignancies in children present at an
advanced stage and have a poor prognosis. Significant
immune suppression was not commonly seen. Associa-
tion of HIV with cancers among children must be kept in
mind by pediatricians especially in NHL. There should be
a high index of suspicion for cancers among HIV-infected
children.Page 2 of 2
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